Modus CEO On Its Plans For An At-Home Injectable For Sickle Cell Crises

 
• By Sten Stovall

Modus Therapeutics has begun a Phase I study with subcutaneously administered sevuparin. Its CEO says this new formulation of its lead asset has the potential to be self-administered by sickle cell disease patients at home for the treatment of vaso-occlusive crises.

SickleCell
No therapies yet exist to treat painful crises, the hallmark of Sickle Cell Disease • Source: Shutterstock

More from Clinical Trials

More from R&D